A Phase I/II clinical trial of ISX9-CPC
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs ISX9 CPC (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- 20 Jan 2025 New trial record
- 13 Jan 2025 According to a IPS HEART media release, company is also pursuing ongoing partnerships with various large pharmaceutical companies while attending the J.P. Morgan Healthcare Conference to partner with them to help rapidly advance both therapies to the clinic.
- 13 Jan 2025 According to a IPS HEART media release, given the successful completion of second pre-IND meeting with the FDA last year (attended by 4 FDA branch chiefs), which also included approving proposed/submitted Phase I/II clinical trial design, for advancing both therapeutics (both cardiac muscle and skeletal muscle in muscular dystrophy) to the clinic.